Maryam H Alrashid1, Ahmad Al-Serri2, Salem H Alshemmari3, Philip Koshi4, Suzanne A Al-Bustan4. 1. Department of Biological Sciences, Faculty of Science, Kuwait University, PO Box 5969, Safat, 13060, Kuwait, Kuwait. maryam.alrashid@ku.edu.kw. 2. Department of Pathology, Faculty of Medicine, Kuwait University, Safat, Kuwait. 3. Department of Medicine, Faculty of Medicine, Kuwait University, Safat, Kuwait. 4. Department of Biological Sciences, Faculty of Science, Kuwait University, PO Box 5969, Safat, 13060, Kuwait, Kuwait.
Abstract
BACKGROUND AND OBJECTIVE: Warfarin is the most widely prescribed oral anticoagulant worldwide. The narrow therapeutic index and the large variation in the inter-individual dose of warfarin are problematic, since the side effects can be lethal. Single nucleotide polymorphisms (SNP) in CYP2C9 and VKORC1 have been shown to significantly affect warfarin dosage toleration and this effect varies among different populations. We aimed to investigate the effect of these SNPs on warfarin dosage in a sample of Kuwaiti patients. METHODS: Kuwaiti patients who were taking a maintenance dose of warfarin were genotyped for CYP2C9*1, *2 and *3 and VKORC1 rs9923231, rs9934438, rs7294 and rs2884737. The association of these SNPs with the warfarin dose was evaluated. RESULTS: For CYP2C9, the CYP2C9 *1/*1 genotype required a higher dose (5.5 ± 3.3 mg/day) compared to non-*1/*1 (3.3 ± 1.7 mg/day) (p = 0.003). For VKORC1, the daily warfarin dose was significantly different (p = 0.001) among the three genotypes of rs9923231, rs9934438 and rs2884737, with carriers of the wild-type genotype requiring the highest dose compared to variant allele carriers (p ≤ 0.001-0.002). There was no association found between the daily warfarin dose and the rs7294 polymorphism. CONCLUSIONS: Our data showed that individuals carrying the wild-type allele of CYP2C9 or VKORC1 rs9923231, rs9934438 or rs2884737 are less sensitive than individuals with the variant alleles of these SNPs and therefore required a higher daily maintenance dose of warfarin. Our study confirms the association between SNPs in CYP2C9 and VKORC1 and warfarin dose tolerance in Kuwaiti patients.
BACKGROUND AND OBJECTIVE:Warfarin is the most widely prescribed oral anticoagulant worldwide. The narrow therapeutic index and the large variation in the inter-individual dose of warfarin are problematic, since the side effects can be lethal. Single nucleotide polymorphisms (SNP) in CYP2C9 and VKORC1 have been shown to significantly affect warfarin dosage toleration and this effect varies among different populations. We aimed to investigate the effect of these SNPs on warfarin dosage in a sample of Kuwaiti patients. METHODS: Kuwaiti patients who were taking a maintenance dose of warfarin were genotyped for CYP2C9*1, *2 and *3 and VKORC1rs9923231, rs9934438, rs7294 and rs2884737. The association of these SNPs with the warfarin dose was evaluated. RESULTS: For CYP2C9, the CYP2C9 *1/*1 genotype required a higher dose (5.5 ± 3.3 mg/day) compared to non-*1/*1 (3.3 ± 1.7 mg/day) (p = 0.003). For VKORC1, the daily warfarin dose was significantly different (p = 0.001) among the three genotypes of rs9923231, rs9934438 and rs2884737, with carriers of the wild-type genotype requiring the highest dose compared to variant allele carriers (p ≤ 0.001-0.002). There was no association found between the daily warfarin dose and the rs7294 polymorphism. CONCLUSIONS: Our data showed that individuals carrying the wild-type allele of CYP2C9 or VKORC1rs9923231, rs9934438 or rs2884737 are less sensitive than individuals with the variant alleles of these SNPs and therefore required a higher daily maintenance dose of warfarin. Our study confirms the association between SNPs in CYP2C9 and VKORC1 and warfarin dose tolerance in Kuwaiti patients.
Authors: P Dorado; M G Sosa-Macias; E M Peñas-Lledó; R E Alanis-Bañuelos; M-L Wong; J Licinio; I Lares-Asseff; A Llerena Journal: Pharmacogenomics J Date: 2010-05-11 Impact factor: 3.550
Authors: E Ramos; A Doumatey; A G Elkahloun; D Shriner; H Huang; G Chen; J Zhou; H McLeod; A Adeyemo; C N Rotimi Journal: Pharmacogenomics J Date: 2013-07-09 Impact factor: 3.550
Authors: Erik Fung; Nikolaos A Patsopoulos; Steven M Belknap; Daniel J O'Rourke; John F Robb; Jeffrey L Anderson; Nicholas W Shworak; Jason H Moore Journal: Semin Thromb Hemost Date: 2012-10-06 Impact factor: 4.180
Authors: Gregory M Cooper; Julie A Johnson; Taimour Y Langaee; Hua Feng; Ian B Stanaway; Ute I Schwarz; Marylyn D Ritchie; C Michael Stein; Dan M Roden; Joshua D Smith; David L Veenstra; Allan E Rettie; Mark J Rieder Journal: Blood Date: 2008-06-05 Impact factor: 22.113
Authors: Simone Rost; Andreas Fregin; Vytautas Ivaskevicius; Ernst Conzelmann; Konstanze Hörtnagel; Hans-Joachim Pelz; Knut Lappegard; Erhard Seifried; Inge Scharrer; Edward G D Tuddenham; Clemens R Müller; Tim M Strom; Johannes Oldenburg Journal: Nature Date: 2004-02-05 Impact factor: 49.962
Authors: Madina R Zhalbinova; Saule E Rakhimova; Ulan A Kozhamkulov; Gulbanu A Akilzhanova; Galina K Kaussova; Kenes R Akilzhanov; Yuriy V Pya; Joseph H Lee; Makhabbat S Bekbossynova; Ainur R Akilzhanova Journal: J Pers Med Date: 2022-05-04
Authors: Maryam H Alrashid; Ahmad Al-Serri; Salem H Alshemmari; Jeethu Anu Geo; Suzanne A Al-Bustan Journal: Cancer Biomark Date: 2021 Impact factor: 4.388